INTRODUCTION
High-risk genotypes of human papillomavirus (HPV) are responsible for the development of >99% of cervical carcinomas. 1 Cervical cancer screening with Papanicolaou (Pap) cytology and HPV DNA cotesting has demonstrated either an increased rate of detection of high-grade cervical intraepithelial neoplasias (CIN of type 2 [CIN-2]/CIN-3) at the initial screening round or a decreased rate of cervical cancer at the second screening round or both compared with Pap cytology testing alone, confirming that Pap and HPV cotesting has greater sensitivity than Pap testing alone in the detection of CIN-3 or higher. [2] [3] [4] Pap cytology and high-risk HPV cotesting for the prevention of cervical cancer in women aged 30 years has been recommended in the United States by the American Society for Colposcopy and Cervical Pathology (ASCCP). In the 2002 and 2004 interim guidelines for cervical cancer screening, 5, 6 a 3-year screening interval was recommended for women with negative Pap (Pap-) and negative HPV (HPV-) test results. 5, 6 The current guidelines, issued in 2012
by the American Cancer Society, the ASCCP, and the American Society for Clinical Pathology, recommend a 5-year screening interval for women aged 30 years with Pap-/HPV-cotesting results. 7 This recommendation is based on published data demonstrating that the risks of CIN-2 or higher and cervical carcinoma in women with Pap-/HPVcotesting results for a 5-year interval are comparable to those in women with a Pap-cytology result for a 3-year interval. Therefore, the risk of co-screening with Pap and HPV at the longer interval is considered small and acceptable. 8, 9 Although Pap cytology and HPV co-screening have increasingly been adopted by hospitals and cervical cancer screening programs in the United States for women aged 30 years, the practice remains relatively underused. 10, 11 To the best of our knowledge, published studies regarding Pap/HPV cotesting are limited. [12] [13] [14] [15] 
MATERIALS AND METHODS

Patient Population
Pap Cytology and HPV Cotesting
Pap cytology specimens were collected using the SurePath Pap collection devices (TriPath Imaging, Burlington, NC). The Pap specimens were prepared at the cytopathology laboratory of MDACC and screened by cytotechnologists according to The Bethesda System for reporting Pap test results. 16 Each Pap specimen classified as abnormal was reviewed by a cytopathologist. HPV testing was also performed on the Pap specimens. The residual SurePath specimen was sent to Quest Diagnostics (Houston, Tex) for HPV DNA testing. HPV DNA was detected by the Hybrid Capture 2 assay (HC2; Qiagen, Valencia, Calif), which collectively tests for 13 high-risk HPV types.
Follow-Up Biopsy
Women with an abnormal follow-up Pap test result and/or HPV result underwent colposcopy and/or biopsy in the Cancer Prevention Center at MDACC according to the guidelines issued by the ASCCP. 13 The follow-up biopsy specimens were processed and interpreted by pathologists at MDACC.
Statistical Analysis
The baseline Pap/HPV cotesting results were stratified according to Pap and/or HPV testing results. Cumulative risks (incidence) of CIN-3 during the 3-year follow-up period were calculated, and descriptive statistics were used to compare groups. The Fisher exact test was used to assess the association between categorical variables. Tests with a P value (2-sided test) <.05 were considered to be statistically significant. All computations were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC). Follow-up data were available for 1986 women who had a baseline Pap/HPV cotesting result, including 1896 Pap cytology results and 183 biopsy findings. The age distribution for these women is shown in Table 2 . Baseline cotesting results of Pap-/HPV1 (31.6%) or Pap1/HPV1 (39.3%) were observed more frequently among those patients aged 40 to 49 years. A baseline cotesting result of Pap1/HPV-was noted more frequently among women aged 50 to 59 years.
RESULTS
Baseline
Three-Year Pap/HPV Cytology Follow-Up
Of the 1896 women who underwent a follow-up Pap test within 3 years after the baseline Pap/HPV cotesting, 1668 (88.0%) had a baseline cotesting result of Pap-/HPV-, 132 (7.0%) had a baseline cotesting result of Pap-/HPV1, 89 (4.7%) had a baseline cotesting result of Pap1/HPV-, and 7 women (0.4%) had a baseline cotesting result of Pap1/ HPV1. The Pap cytology follow-up results for women with a baseline Pap/HPV cotesting result are summarized in Table 3 .
Of these 1896 women, 1752 (92.4%) had a Pap test result of negative for intraepithelial lesion or malignancy. Of the 1668 women for whom a baseline Pap-/HPVcotesting result and a follow-up result were available, 1561 (93.6%) had a Pap test follow-up result of negative for intraepithelial lesion or malignancy. Of these 1668 In women with a baseline Pap-/HPV1 cotesting result, the 3-year cumulative rate of HPV positivity was 23.8% (24 of 101 women) and the 3-year cumulative rate of abnormal follow-up Pap test results was 19.7% (26 of 132 women), including 7 LSIL results and 1 HSIL result. Among women with a baseline Pap1/ HPV-cotesting result, the 3-year cumulative HPV1 rate was 2.6% (2 of 77 women) and the 3-year cumulative rate of abnormal follow-up Pap test results was 7.9% (7 of 89 women).
Three-Year Follow-Up Biopsy
During the 3-year follow-up period, 183 women with a baseline Pap/HPV cotesting result underwent cervical biopsy. CIN was diagnosed in 58 of these women (34 cases of CIN-1, 14 cases of CIN-2, and 10 cases of CIN-3). The cumulative risk of CIN was stratified and calculated by the number of women in each baseline Pap/HPV cotesting category (Table 4) or by baseline Pap cytology or HPV testing category (Table 5 ) with all available follow-up results, including both Pap test and biopsy results. Table 4 illustrates the risks of CIN in women with a baseline Pap/ HPV cotesting result. The highest 3-year cumulative risk of CIN-3 was observed among women with a baseline Pap1/HPV1 cotesting result (12.5%); the rates were found to be lower in women with a baseline Pap-/HPV1 (1.5%) or Pap-/HPV-(0.06%) cotesting result. None of the women with a baseline Pap1/HPV-cotesting result was shown to have a CIN-3 result on follow-up biopsy Abbreviations: 2, negative; 1, positive; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; Pap, Papanicolaou.
( Table 4 ). The risk of CIN-3 was found to be significantly different between women with a baseline Pap-/HPVcotesting result and those with a baseline Pap-/HPV1 cotesting result (P 5 .0155) or those with a baseline Pap1/HPV1 cotesting result (P<.0001). Similarly, the highest 3-year cumulative risks of CIN-2 or CIN-1 were observed among women with a baseline Pap1/HPV1 cotesting result; these risks were found to be successively lower in women with a baseline Pap-/HPV1, Pap1/ HPV-, or Pap-/HPV-cotesting result (Table 4) . Age stratification demonstrated a similar CIN-3 risk level in women aged 30 to 39 years (1 of 156 women; 0.64%), women aged 40 to 49 years (4 of 676 women; 0.59), and women aged 50 to 59 years (5 of 882 women; 0.57%). No cases of CIN-3 were observed in women aged 60 years. When the baseline results were analyzed separately by individual test (ie, HPV or Pap), women with a baseline HPV1 testing result had a significantly higher risk of CIN-3 compared with women with a baseline HPV-testing result (4.8% vs 0.06%; P<.0001). Similarly, women with a baseline Pap1 testing result were found to have a significantly higher risk of CIN-3 compared with those with a baseline Pap-testing result (3.8% vs 0.17%; P<.0001). The risks of CIN-2 or CIN-1 demonstrated similar patterns (Table 5) .
DISCUSSION
In the current retrospective study, we reviewed the 3-year follow-up data, including Pap cytology, Pap/HPV cotesting, and biopsy, for women who underwent baseline Pap/ HPV cotesting screening in the Cancer Prevention Center at MDACC over a 2-year period. We observed a very low 3-year cumulative risk of CIN-3 or higher (0.06%) among women with a baseline Pap-/HPV-cotesting result. The highest cumulative risk of CIN-3 was observed in women with a baseline Pap1/HPV1 cotesting result, with lower risks noted for women with a baseline Pap-/HPV1 or Pap1/HPV-cotesting result. The findings of the current study indicate that Pap/HPV cotesting has a high efficacy in screening the population of women aged 30 years and support using Pap/HPV cotesting for the prevention of cervical cancer as recommended by the current guidelines. The findings of the current study also suggest that stratifying risk by Pap/HPV cotesting results may help to optimize patient triage and follow-up. The fact that only 1986 of the 6357 women who underwent baseline screening at the study center during the 2-year study period had follow-up testing results, either Pap cytology or biopsy, during the 3-year follow-up period may be attributed to the patient population screened at the Cancer Prevention Center at MDACC. Many of the patients visiting the center for cancer diagnosis or therapy come from other regions or states, and the majority received follow-up screening for cervical cancer prevention near their home. Therefore, the current study cohort represents a predominantly local, low-risk population similar to that previously reported in the Houston area. 17 Furthermore, the women in the current study cohort were from the cervical cancer screening population seen at the Cancer Prevention Center at MDACC, and therefore were separate from patients with cervical dysplastic lesions, who were treated and monitored in the gynecology clinics. The baseline Pap/HPV cotesting results in the current study are similar to the published data regarding the Kaiser Permanente Northern California (KPNC) cohort (Pap-/HPV-: 92.6% vs 92.5%; Pap-/HPV1: 3.1% vs 3.7%; Pap1/ HPV-: 2.9% vs 2.5%; and Pap1/HPV1: 1.4% vs 1.4%). 13 The main difference between the 2 studies is the older age of the women in the current study cohort (median, 54 years, whereas the median age of the KPNC cohort was 46 years). Consequently, the rate of HPV positivity in women with ASC-US was relatively low, which is consistent with the data reported from a large study cohort in the United States. 10 In the current study cohort, no cases of cervical or endocervical carcinoma were identified during the 3-year follow-up period, most likely because of the low-risk and relatively older screening population. Therefore, we used CIN-3 as an end disease for risk assessment during the 3-year follow-up period after baseline Pap/HPV cotesting. Several published studies have examined Pap/HPV cotesting for women aged 30 years in the United States.
Original Article
Katki et al investigated cotesting in a large cohort of patients being treated at KPNC. 9 Using the HC2 HPV assay to identify HPV, they reported a 3-year cumulative risk of CIN-3 or higher of 0.047% and a 5-year cumulative risk of 0.16% in women with a baseline Pap-/HPVcotesting result. In another published study of Pap/HPV cotesting that used the HC2 HPV assay, Zhao et al reported a cumulative risk of 0.17% of CIN-3 or higher among women with a baseline Pap-/HPV-cotesting result, but the follow-up period in that study was >3 years (mean, 44 months). 18 In a published study of a large study cohort (Addressing the Need for Advanced HPV Diagnostics [ATHENA]), Wright et al reported a 3-year cumulative risk of 0.3% of CIN-3 or higher among women with a baseline Pap-/HPV-cotesting result. 19 Thus, the 3-year cumulative risk of 0.06% of CIN-3 in women with a baseline Pap-/HPV-cotesting result noted in the current study is within the lower range of the risks reported in the published studies. The reason for the differences in the reported cumulative risk of CIN-3 among the ATHENA and KPNC studies and the current study is not clear. Although a different HPV assay was used in the ATHENA study (cobas HPV Assay; Roche Molecular Diagnostics, Pleasanton, Calif), the differences in the cumulative risk of CIN-3 or higher noted in these studies may reflect differences in the study population rather than in the testing method. The baseline HPV positivity rate was found to be higher in the ATHENA study cohort compared with the current study cohort (10.5% vs 4.5%). The rate of abnormal baseline Pap cytology testing results (ASC-US) also was found to be higher in the ATHENA study cohort compared with the current study (6.4% vs 4.3%), indicating that the ATHENA study cohort represented a population at higher risk whereas that in the current study represented a low-risk population. 19 Nevertheless, the ATHENA study demonstrated that the 3-year cumulative risk of CIN-3 or higher was significantly lower in women with a baseline Pap-/HPV-cotesting result compared with women with a Pap-cytology testing result alone (0.3% vs 0.8%), thereby supporting the recommendation that integrating HPV testing into cervical cancer screening can significantly improve the efficacy of the screening for the prevention of cervical cancer. 19 In a retrospective study of Pap/HPV cotesting results in women undergoing cervical biopsies, Blatt et al 15 reported that a positive Pap/HPV cotesting result had a higher efficacy for CIN-3 or higher than either a positive HPV-only result or a positive Paponly result. However, the cumulative risk of CIN-3 in women with a Pap-/HPV-cotesting result could not be assessed because of the study design. 15 The screening interval for Pap/HPV cotesting for women aged 30 years was extended from 3 years to 5 years in the revised US guidelines issued in 2012. 7 Although Pap/HPV cotesting has been increasingly adopted in the United States, rescreening within 3 years remains common. 10, 11, 13 This may reflect the reluctance of clinicians or women to wait 5 years for rescreening. Recently, the increased risk of cervical cancer associated with longer screening intervals has drawn concerns regarding the 5-year screening interval that currently is recommended. The report by Katki et al demonstrating that the cumulative risk of CIN-3 or higher in the KPNC study over a 5-year screening interval (0.16%) was 3-fold higher than that noted over a 3-year interval (0.047%) and the report by Gage et al indicating that cancer risk doubled from 0.007% at 3 years to 0.014% at 5 years after a Pap-/ HPV-cotesting result highlight the issue of whether a 5-year rescreening interval is as safe as a 3-year rescreening interval for the prevention of cervical cancer. 9, 20 In a more recent study, Gage et al also reported a greater overall cumulative risk of CIN-3 when the rescreening interval was extended from 3 years (0.39% in the New Mexico HPV Pap Registry vs 0.46% in KPNC) to 5 years (0.54% in the New Mexico HPV Pap Registry vs 0.59% in KPNC) for women with a Pap-/HPV-cotesting result. 14 The clinical implication of a prolonged rescreening interval after Pap/HPV cotesting remains uncertain because to the best of our knowledge the published data regarding a 5-year follow-up interval are very limited. Luyten et al compared rates of CIN-3 or higher at the time of baseline Pap/ HPV cotesting and at 5-year follow-up screening and found a significant decrease in the rate of CIN-3 or higher from the baseline screening (0.87%) to the 5-year followup screening (0.05%). 21 Although it was not clear whether the decline in the rate of CIN-3 or higher was associated with age, as documented in published studies, 14, 22 the study demonstrated a very low risk of CIN-3 or higher after Pap/HPV cotesting, even at a 5-year screening interval.
The results of the current study support the use of HPV testing results for risk stratification (Fig. 1 ). An HPV1 result predicted a higher risk of CIN-3 than a Pap1 cytology result. The 3-year follow-up biopsy data from the current study demonstrated a significantly lower risk of CIN-3 in women with an HPV-test result compared with women with an HPV1 test result (0.06% vs 4.8%). The findings of the current study also indicate that risk stratification by Pap/HPV cotesting result is more accurate for the risk prediction of CIN-3 or higher than the Pap test alone, a conclusion that is in keeping with the findings from large study cohorts such as the KPNC cohort. 9 When using high-risk HPV testing as a primary screening method for the prevention of cervical cancer, a 3-year rescreening interval is preferred because the prospective US data are insufficient to support rescreening intervals beyond 3 years. 23, 24 The data from the current study demonstrate that if HPV testing were used as a primary screening tool, the risk of CIN-3 associated with an HPV-result would be the same as that associated with a Pap-/HPVcotesting result (Table 4) . However, the risk of CIN2 would increase from 0.12% in women with a Pap-/HPVcotesting result to 0.2% in women with an HPV-testing result. However, the current study data are limited in that they represent a relatively small cohort with low numbers of end diseases (>CIN-3) in a low-risk population.
With the approval by the US Food and Drug Administration of the cobas HPV testing assay (Roche Molecular Diagnostics) for primary cervical cancer screening and the new guidelines recommending HPV-based cervical cancer screening, further clinical studies are required to compare the efficacy of HPV alone and Pap/HPV cotesting for the prevention of cervical cancer. 
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